Latest From F-star GmbH
Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.
Ghent, Belgium-based start-up, AgomAb Therapeutics NV secures funds and license to develop HGF-mimetic agonistic monoclonal antibodies for regeneration of damaged tissues.
The pharma, biotech and allied industries came together to celebrate another year of excellence at the 14th Annual Scrip awards in London on Nov. 28, hosted by the Right Honourable Lord (William) Hague.
Denali Therapeutics will pay around $470m in upfront and milestone payments to acquire its CNS bispecific antibody development partner F-star Gamma, lending credence to F-star’s business model of individual, asset-specific spin offs.
- Synthesis Technologies, Production Processes
- Large Molecule
- Therapeutic Areas
- f-star Biotechnology Research & Development Co.
- Western Europe
- Parent & Subsidiaries
- F-star GmbH
- Senior Management
Eliot Forster, PhD, CEO
Darlene Deptula-Hicks, CFO
Jane Dancer, PhD, CBO
Neil Brewis, PhD, CSO
Tolga Hassan, COO
Louis Kayitalire, MD, CMO
- Contact Info
Phone: (43) 72055 4215
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.